Special Issue

Advances in Neuroendocrine Cancer Metabolism

Message from the Guest Editors

Neuroendocrine neoplasms (NEN) are heterogeneous tumors with increasing incidence, arising from neuroendocrine cells throughout the body, and have the unique capacity to secrete bioactive molecules that can cause specific clinical syndromes. Dysregulated metabolism in cancer is of great relevance and a better knowledge of cell proliferation is essential to understand the mechanisms of tumor formation and cancer progression. Advances in neuroendocrine cancer metabolism may consider the patient's entire clinical journey, from diagnosis to therapy. In NEN, different metabolic pathways are analyzed, and various positron emission tomography (PET) radiotracers and the analysis of different characteristic metabolic changes in tumor cells could be useful in identifying novel biomarkers of potential clinical use, improving diagnostic and patient outcomes, and designing tailored therapies.

Guest Editors

Dr. Roberta Modica

Endocrinology Unit, Department of Clinical Medicine and Surgery, ENETS Center of Excellence, University "Federico II" of Naples, 80131 Naples, Italy

Prof. Dr. Renata Simona Auriemma

Endocrinology Unit, Department of Clinical Medicine and Surgery, "Federico II" University of Naples, Via Sergio Pansini 5, 80131 Naples, Italy

Deadline for manuscript submissions

closed (15 June 2024)

Metabolites

an Open Access Journal by MDPI

Impact Factor 3.7
CiteScore 6.9
Indexed in PubMed

mdpi.com/si/171304

Metabolites
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
metabolites@mdpi.com

mdpi.com/journal/metabolites



Metabolites

an Open Access Journal by MDPI

Impact Factor 3.7
CiteScore 6.9
Indexed in PubMed

mdpi.com/journal/metabolites

About the Journal

Message from the Editor-in-Chief

The metabolome is the result of the combined effects of genetic and environmental influences on metabolic processes. Metabolomic studies can provide a global view of metabolism and thereby improve our understanding of the underlying biology. Advances in metabolomic technologies have shown utility for elucidating mechanisms which underlie fundamental biological processes including disease pathology. *Metabolites* is proud to be part of the development of metabolomics and we look forward to working with many of you to publish high quality metabolomic studies.

Editor-in-Chief

Dr. Amedeo Lonardo
Internal Medicine, Ospedale Civile di Baggiovara, Azienda Ospedaliero-Universitaria, 41126 Modena, Italy

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Biochemistry and Molecular Biology) / CiteScore - Q2 (Endocrinology, Diabetes and Metabolism)

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 16.7 days after submission; acceptance to publication is undertaken in 3.6 days (median values for papers published in this journal in the second half of 2025).

MDPI